Thyrocare to acquire diagnostic and pathological services of Vimta Lab
Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs.
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.

Low Price Shares
0 mins read . Dec 18, 2024

Nifty 50 Top 10 Stocks
0 mins read . Dec 18, 2024

Best Stocks in 2025
0 mins read . Dec 18, 2024

Explore our products
Unlimited Trading starting at ₹249
Open Trading Account